[go: up one dir, main page]

HK1147070A - Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents - Google Patents

Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents Download PDF

Info

Publication number
HK1147070A
HK1147070A HK11101194.9A HK11101194A HK1147070A HK 1147070 A HK1147070 A HK 1147070A HK 11101194 A HK11101194 A HK 11101194A HK 1147070 A HK1147070 A HK 1147070A
Authority
HK
Hong Kong
Prior art keywords
treatment
combination
parp inhibitor
tumor agents
cancer
Prior art date
Application number
HK11101194.9A
Other languages
Chinese (zh)
Inventor
Barry M. Sherman
Charles Bradley
Valeria S. Ossovskaya
Original Assignee
Bipar Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bipar Sciences, Inc. filed Critical Bipar Sciences, Inc.
Publication of HK1147070A publication Critical patent/HK1147070A/en

Links

HK11101194.9A 2007-11-12 2008-11-12 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents HK1147070A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60/987,335 2007-11-12
US61/012,364 2007-12-07
US61,058,528 2008-06-03

Publications (1)

Publication Number Publication Date
HK1147070A true HK1147070A (en) 2011-07-29

Family

ID=

Similar Documents

Publication Publication Date Title
IL205633A0 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2009064738A9 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
IL206209A0 (en) Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
EP2038041A4 (en) Therapeutic compounds and their use in cancer
ZA200808334B (en) Cancer treatment combining lymphodepleting agent with CTLs and cytokines
SI2139483T1 (en) Combination therapies comprising a quinoxaline inhibitor of pi3k-alpha for use in the treatment of cancer
EP2211854A4 (en) Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
SI2338487T1 (en) Combination therapy with PARP inhibitors
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL187898A0 (en) Parp modulators and treatment of cancer
ZA200908477B (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
IL199609A0 (en) Antifolate agent combinations in the treatment of cancer
HUE037109T2 (en) Endoxifen for use in the treatment of cancer
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
PL2898887T3 (en) Combined telomerase inhibitor and gemcitabine for the treatment of cancer
EP2025347A4 (en) PROPHYLACTIC AND THERAPEUTIC AGENT FOR CANCER
EP2144887A4 (en) Dosages and methods for the treatment of cancer
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
GB0607949D0 (en) Mono and combination therapy
GB0607946D0 (en) Mono and combination therapy
IL193663A0 (en) Thiadiazole compounds and their use in phototherapy
HK1147070A (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
HK1147071A (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AU2005339587A8 (en) Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
EP2224932A4 (en) Cancer treatment using cox-2 inhibitor and antimetabolite combinations